Drug Delivery Systems Using Surface Markers for Targeting Cancer Stem Cells

Abstract

The innate abilities of cancer stem cells (CSCs), such as multi-drug resistance, drug efflux, quiescence and ionizing radiation tolerance, protect them from most traditional chemotherapeutics. As a result, this small subpopulation of persistent cells leads to more aggressive and chemoresistant cancers, causing tumour relapse and metastasis. This subpopulation is differentiated from the bulk tumour population through a wide variety of surface markers expressed on the cell surface. Recent developments in nanomedicine and targeting delivery methods have given rise to new possibilities for specifically targeting these markers and preferentially eliminating CSCs. Herein, we first summarize the range of surface markers identifying CSC populations in a variety of cancers; then, we discuss recent attempts to actively target CSCs and their niches using liposomal, nanoparticle, carbon nanotube and viral formulations.

Recent Advances in Nanotechnology-Based Drug Delivery Systems for the Diagnosis and Treatment of Reproductive Disorders

“…Additionally, this targeted drug delivery approach has shown promising results in preclinical studies, highlighting its potential as a future treatment option for ovarian cancer. , Surface markers specific to cancer stem cells (CSCs) serve as potential therapeutic targets for the elimination of CSCs. Active targeting can be achieved by conjugating targeting moieties to drug-carrying nanoparticles. , These moieties can specifically bind to the markers expressed on CSCs. Following binding, drug release can be triggered by external and internal stimuli .…”

“…Active targeting can be achieved by conjugating targeting moieties to drug-carrying nanoparticles. 190,191 These moieties can specifically bind to the markers expressed on CSCs. Following binding, drug release can be triggered by external and internal stimuli.…”